Valneva SE, Chikungunya

Valneva reports Phase 2 results in children for its chikungunya vaccine
Valneva (VALN) announced results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its
Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision
Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already at Day 15 and Day 29 post-vaccination, confirming the excellent immunogenicity previously observed in adults and adolescents 6,7,8,9,10.
Valneva shares positive phase 3 results for chikungunya vaccine in adolescents
Valneva has shared positive results from a late-stage study of its single-dose chikungunya vaccine in adolescents aged 12 to 17 years. The vaccine, Ixchiq, is already approved in the US, Europe and Canada to prevent the mosquito-borne viral disease in individuals aged 18 years and older.
Valneva gains after new Phase 3 data for chikungunya vaccine in adolescents
ADRs traded higher in the premarket on Tuesday after the French biotech posted additional data for its FDA-approved chikungunya vaccine, Ixchiq, from a Phase 3 trial for people aged 12–17 years old in Brazil.
Valneva announces positive outcomes from chikungunya vaccine trial
Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus (CHIKV) vaccine in adolescents. The trial demonstrated a ‘sustained’ sero-response rate of 98.
Valneva Is A 'Buy' As A First-Mover In Chikungunya
Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...
pharmaphorum3d
Valneva gets $41m grant to roll out chikungunya vaccine
Valneva has been awarded funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and EU to expand access to its recently approved vaccine for chikungunya, a potentially life ...
Positive Outlook for Valneva: Favorable Vaccine Trials and Expanding Market Potential
H.C. Wainwright analyst Edward White reiterated a Buy rating on Valneva (VALN – Research Report) today and set a price target of $18.00.Invest ...
Indiatimes23d
Chikungunya patients back in care as symptoms linger
Maharashtra witnessed a significant rise in chikungunya cases this year, with 5,757 infections. Patients are experiencing prolonged after-effects like joint pain, fatigue, and neurological ...
Medscape4d
Rapid and Real-time Assays for Detection and Quantification of Chikungunya Virus
A definitive diagnosis of Chikungunya infection can be made only with the aid of laboratory support since clinically, symptoms resemble those of dengue fever. Laboratory diagnosis is therefore ...
Nothing Stops Samantha Ruth Prabhu's Workout Session, Not Even Chikungunya
On the work front, she was last seen in the action series Citadel: Honey Bunny, where she played an agent. Written by Sita R. Menon and directed by Raj & DK (Raj Nidimoru and Krishna DK), Citadel: ...
devdiscourse10d
HS Prannoy Battles Back: Resilience and Redemption on the Badminton Court
Indian badminton player HS Prannoy is overcoming challenging setbacks, including health issues, to make a comeback.